Skip to content


    DEA Class; Rx

    Common Brand Names; Hycofenix

    • Antitussives, Narcotic Combos

    Hydrocodone: Antitussive; narcotic agonist analgesic

    Pseudoephedrine: Decongestant; alpha adrenergic agonist

    Guaifenesin: Reduces viscosity of secretions by increasing amount of respiratory tract fluid

    Temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions when these conditions are complicated by tenacious mucus or mucus plugs and congestion

    Documented hypersensitivity

    Patients receiving MAOI therapy or within 14 days of stopping such therapy

    Narrow angle glaucoma

    Urinary retention

    Severe hypertension

    Severe coronary artery disease


    • Respiratory depression

    • Drug dependence

    • Increased intracranial pressure

    • Decreased mental alertness with impaired mental and/or physical abilities

    • Paralytic ileus


    • CNS effects (eg, insomnia, dizziness, weakness, tremor, or convulsions)

    • Cardiovascular system effects (eg, arrhythmias, or increased blood pressure), cardiovascular collapse with accompanying hypotension

    Hydrocodone produces dose-related respiratory depression by directly acting on brain stem respiratory centers

    Hydrocodone can produce drug dependence and tolerance may develop upon repeated administration; prescribe with same degree of caution as use of other opioid drugs

    Respiratory depression effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure

    Hydrocodone may produce marked drowsiness and impair mental and physical abilities required for hazardous activities (eg, driving); concurrent use with alcohol or other CNS depressants should be avoided

    Caution in patients with acute abdominal conditions; hydrocodone may obscure the diagnosis or clinical course of acute abdominal illness

    Concurrent use of anticholinergics with hydrocodone may cause paralytic ileus

    Use of MAOIs or TCAs with hydrocodone may increase the effect of either the antidepressant or hydrocodone; do not use with MAOIs or within 14 days of stopping an MAOI

    Pseudoephedrine can produce cardiovascular and CNS effects in some patients (eg, insomnia, dizziness, weakness, tremor, or arrhythmias); CNS stimulation with convulsions or cardiovascular collapse with accompanying hypotension has also been reported

    Do not for persistent or chronic cough (eg, associated with smoking, asthma, chronic bronchitis, or emphysema), or where cough is accompanied by excessive phlegm

    Measure dose with accurate milliliter measuring device to avoid overdose

    Caution with diabetes, thyroid disease, Addison disease, prostatic hypertrophy, urethral stricture, and asthma

    Caution with severe renal or hepatic impairment

    Pregnancy category: C

    Caution; hydrocodone and pseudoephedrine are known to be excreted in human milk; no studies have been performed to determine if guaifenesin is excreted into breastmilk


    10 mL PO q4-6hr; not to exceed 4 doses (40 mL) per 24 hr



    <18 years: Safety and efficacy not established

    Use of hydrocodone in children aged <6 years is associated with fatal respiratory depression


    oral solution: Schedule III

    • (2.5mg/30mg/200mg)/5mL